One video visit
All states
GLP-1 weight loss in Pennsylvania
- Visit type
- No video visit required
- Licensing
- Pennsylvania State Board of Medicine
- Updated
- Licensed by
- Pennsylvania State Board of Medicine
- Telehealth
- No video visit required
- Semaglutide injections
- Available
- Tirzepatide injections
- Available
- Medicaid
- Limited coverage
- Shipping
- 2–3 business days
Pennsylvania residents can now access GLP-1 medications like semaglutide and tirzepatide through telehealth — whether you're in Philly, Pittsburgh, the Lehigh Valley, or a rural county without a nearby obesity medicine specialist. Pallas Health connects you with a board-certified provider licensed in Pennsylvania who can evaluate your eligibility in under 5 minutes and, if appropriate, prescribe medication that ships to any Pennsylvania address in a few business days.
How telehealth prescribing works in Pennsylvania
Pennsylvania permits licensed providers to use telehealth to establish a patient relationship and prescribe non-controlled medications like GLP-1s, including synchronous video and, in appropriate cases, asynchronous review under the Pennsylvania Telemedicine Act.
Pennsylvania requires any provider writing a prescription to a Pennsylvania resident to hold an active Pennsylvania medical license — out-of-state licensure is not sufficient. Under the Pennsylvania Telemedicine Act (signed in 2024) and State Board of Medicine guidance, licensed physicians may use telehealth to establish the provider-patient relationship and prescribe non-controlled medications, including via synchronous video and, in appropriate cases, asynchronous review when the standard of care is met. Every Pallas clinician who treats Pennsylvania patients is individually licensed by the Pennsylvania State Board of Medicine or State Board of Osteopathic Medicine. GLP-1s are not controlled substances, so Pennsylvania's separate PDMP and controlled-substance telemedicine requirements do not apply here, but our providers still take a complete history, screen for contraindications like personal or family history of medullary thyroid carcinoma, and schedule follow-up visits to monitor response and titrate the dose.
Medicaid & insurance in Pennsylvania
Pennsylvania Medical Assistance covers GLP-1s for type 2 diabetes with prior authorization, but eliminated coverage for weight-loss indications effective January 1, 2026. Compounded GLP-1s are not covered. Pallas is a cash-pay telehealth service. Medicaid and private insurance do not apply to our prescriptions; pricing is flat and disclosed up front.
Simple cash-pay pricing in Pennsylvania
No insurance, and the same price in every Pennsylvania ZIP code. You see your full price during intake, before you pay anything. One plan price covers your US-licensed provider, check-ins, dose adjustments and care-team messaging, with no membership fee. Medication ships free, and nothing is charged until a clinician prescribes. Cancel anytime. Your clinician helps determine which option is appropriate for you.
Compounded
- Semaglutide injectionsFrom $139
- Tirzepatide injectionsFrom $179
Brand-name
- Wegovy® injectionsFrom $499
- Zepbound® injectionsFrom $499
- Ozempic® injectionsFrom $499
- Mounjaro® injections$1,099/mo
- Wegovy® pillFrom $299
- Foundayo™ pillFrom $299
Semaglutide vs tirzepatide in Pennsylvania
Both are once-weekly injections available to Pennsylvania patients through Pallas, as compounded preparations and as the FDA-approved brand-name products. They work differently: semaglutide activates the GLP-1 receptor, while tirzepatide activates both the GLP-1 and GIP receptors — two of the gut hormones that regulate appetite and fullness.
In SURMOUNT-5, the head-to-head clinical trial of the FDA-approved products, Zepbound® (tirzepatide 10 mg or 15 mg weekly) produced greater average weight loss than Wegovy® (semaglutide 1.7 mg or 2.4 mg weekly) — 20.2% versus 13.7% of body weight over 72 weeks — with broadly similar tolerability. That trial predates Wegovy®'s higher 7.2 mg weekly dose, which reached 18.7% average weight loss over 72 weeks in the separate STEP UP trial; separate trials do not provide a direct comparison. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary.
Cost and track record differ too: compounded semaglutide renews at $199 every 4 weeks versus $299 for tirzepatide (full terms in the questions below), and semaglutide has the longer post-market record. Which medication fits your health history, goals, and budget is a decision you make with a clinician licensed in Pennsylvania — our full semaglutide vs tirzepatide comparison covers the deeper differences.
Cities served in Pennsylvania
Partner pharmacies ship to every ZIP code in Pennsylvania, including:
- Philadelphia
- Pittsburgh
- Allentown
- Erie
- Reading
- Scranton
- Bethlehem
- Lancaster
Pennsylvania GLP-1 questions
Start the online intake (about 5 minutes). A Pennsylvania-licensed clinician reviews it by secure message, and if a GLP-1 is appropriate, a US-licensed pharmacy ships it to you in 2–3 business days.
Same intake as semaglutide. If appropriate, a Pennsylvania-licensed clinician can prescribe compounded tirzepatide or FDA-approved Zepbound® or Mounjaro®, and explains which fits you.
Yes. A Pennsylvania-licensed clinician can prescribe it for you with a documented clinical reason, and a US-licensed compounding pharmacy prepares it per patient. Brand-name Wegovy® is also available.
Yes. Pennsylvania nurse practitioners prescribe under a collaborative agreement filed with the State Board of Nursing. GLP-1s are not controlled substances, so they can be prescribed by telehealth.
Several do. Check that its clinicians are licensed in Pennsylvania, that it uses US-licensed compounding pharmacies, and that it is LegitScript-certified. Pallas serves Pennsylvania.
No. Pennsylvania allows a licensed clinician to review your intake by secure message and prescribe without a scheduled video call. They may ask for a video visit only if your history calls for it.
Medical Assistance covers GLP-1s for type 2 diabetes; weight-loss coverage ended January 1, 2026. Compounded GLP-1s are not covered. Pallas is cash-pay, so Medicaid rules do not apply.
Most Pennsylvania patients receive their medication within 2–3 business days of the pharmacy filling the prescription. Philadelphia and Pittsburgh ship fastest; rural ZIP codes may take an extra day.
One flat cash-pay price, the same in every Pennsylvania ZIP code, no insurance needed. It covers your clinician, check-ins and messaging, and medication ships free once prescribed.
A Pennsylvania-licensed clinician decides after reviewing your intake. GLP-1s are generally considered at a BMI of 30 or more, or 27 or more with a condition like high blood pressure.
Wegovy®, Ozempic®, Zepbound® and Mounjaro® are FDA-approved. Compounded semaglutide and tirzepatide are made per patient by US-licensed pharmacies and are not FDA-approved. Your clinician decides.
Yes. Tell your clinician your current medication, dose and everything else you take during intake. If appropriate, they continue you at a comparable dose. Don't change a prescription on your own.
Most patients use a once-weekly injection with a very fine needle. A daily tablet is available on request. Your clinician confirms which form is appropriate for you.
Mostly stomach-related: nausea, constipation or diarrhea, usually mildest when the dose is raised slowly. They are avoided in pregnancy and with a personal or family history of medullary thyroid cancer or MEN2.
You answer health questions online in about 5 minutes. A Pennsylvania-licensed clinician reviews it by secure message, and if a GLP-1 is appropriate, a licensed pharmacy ships it in 2–3 business days.
Your first order arrives in 2–3 business days, and most patients start low and step up gradually. Your plan renews on a set schedule so refills arrive before you run out; change or cancel anytime in the portal.
Compounded semaglutide injections are $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. Your clinician, check-ins and messaging are included; shipping is free.
Compounded tirzepatide injections are $179 first month, then $299 every 4 weeks, charged once a clinician prescribes. Cancel anytime. Your clinician, check-ins and messaging are included; shipping is free.
Yes. Wegovy®, Zepbound® and Foundayo™ are FDA-approved for weight management, Ozempic® and Mounjaro® for type 2 diabetes. All are cash-pay: pens from $499 first month, daily pills from $299.
Medical Assistance covers GLP-1s for type 2 diabetes; weight-loss coverage ended January 1, 2026. Compounded GLP-1s are not covered. Pallas is cash-pay, so Medicaid rules do not apply.
Two cash-pay paths: stay on Wegovy® or Zepbound® from $499 first month, or a compounded plan from $139 first month if a licensed clinician finds it appropriate. Tell your clinician your current dose.
A decision for you and your clinician. Semaglutide costs less and has the longer track record; tirzepatide acts on two gut-hormone receptors instead of one. The comparison above covers the trials.
Pallas serves all of Pennsylvania with one price for compounded semaglutide: $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. No video visit is required.
Rule changes affecting Pennsylvania
- 2026-07-27 California, South Carolina, and Pennsylvania Medicaid programs eliminated coverage of GLP-1s for weight-loss indications effective January 1, 2026 (Medi-Cal removed Wegovy®, Zepbound®, and Saxenda® for members 21 and older; type 2 diabetes coverage continues in all three, and Medi-Cal keeps narrow exceptions such as Wegovy® for cardiovascular risk reduction). With New Hampshire, logged July 25, all four eliminations reported by KFF are now reflected in the tracker.Medi-Cal Rx provider bulletins (October and December 2025) and KFF Medicaid GLP-1 coverage research; surfaced by our automated source check (PR #45).
From our state-by-state rules tracker. Get an email when a rule changes.
Pallas offers both FDA-approved and compounded medications. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Eligibility and treatment are determined by a US-licensed clinician; results vary. Private pay only (no insurance). Operated by Brentmoor, Inc.